Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Update

Alzamend Neuro, Inc. (NASDAQ:ALZN) was the recipient of a large increase in short interest during the month of October. As of October 15th, there was short interest totalling 228,400 shares, an increase of 121.3% from the September 30th total of 103,200 shares. Approximately 5.4% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,720,000 shares, the days-to-cover ratio is currently 0.1 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Alzamend Neuro stock. Virtu Financial LLC bought a new stake in Alzamend Neuro, Inc. (NASDAQ:ALZN) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 26,482 shares of the company’s stock, valued at approximately $26,000. Virtu Financial LLC owned about 0.38% of Alzamend Neuro at the end of the most recent quarter. 49.61% of the stock is owned by institutional investors and hedge funds.

Alzamend Neuro Price Performance

NASDAQ:ALZN traded down $0.01 during trading hours on Friday, reaching $1.61. 94,250 shares of the company traded hands, compared to its average volume of 545,744. Alzamend Neuro has a 1-year low of $1.40 and a 1-year high of $30.00. The firm’s 50-day moving average is $2.10 and its 200-day moving average is $4.00. The stock has a market cap of $12.85 million, a P/E ratio of -1.63 and a beta of -0.03.

Alzamend Neuro (NASDAQ:ALZN) last posted its quarterly earnings data on Wednesday, September 11th. The company reported ($1.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.38) by $1.13. As a group, research analysts predict that Alzamend Neuro will post -14.27 earnings per share for the current year.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.